Cheon Byeongnyeon, CEO of Woojeong Bio, Receives Commendation from National Assembly Health and Welfare Committee

Cheon Byeong-nyeon, CEO of Woojung Bio, received the 2023 National Assembly Commendation in the field of science and technology, awarded by the Health and Welfare Committee.

Cheon Byeong-nyeon, CEO of Woojung Bio
Photo by Lee Chun-hee

At the 2023 National Assembly Commendation Award Ceremony held on the 21st at the National Assembly Members' Office Building, CEO Cheon was recognized for his contributions to revitalizing the innovative ecosystem for new drug development through the establishment of a bio cluster, and was selected as the recipient of the Health and Welfare Committee Commendation.

Previously, in 2021, CEO Cheon was also awarded the Presidential Citation as an industrial technology contributor.

Woojung Bio completed the establishment of 'Woojung Bio New Drug Cluster (Wooshin Cluster)', the first private-led new drug development cluster in Korea, in 2021. The following year, it opened the shared research institute 'LAB CLOUD', was selected as a new private-led investment-type TIPS (Tech Incubator Program for Startups) operator in 2023, and was designated as a startup incubation center, continuously growing as an open innovation bio research platform to accelerate new drug development.

CEO Cheon said, "I am very pleased to be recognized for my efforts to contribute to the domestic new drug development ecosystem since founding the company in 1987," adding, "Going forward, I will take the lead in building a bio win-win business ecosystem centered on Wooshin Cluster, which has a systematic and comprehensive new drug development infrastructure."